Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Goebell

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
European Urology|May 9, 2015
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell CancerChristian Eichelberg, Walter L Vervenne, Maria De Santis, et al.
Future Oncology (London, England)|November 24, 2025
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tractThomas Powles, Scott T Tagawa, Christof Vulsteke, et al.
Urologic Oncology|March 23, 2020
Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trialNatalya Benderska-Söder, Jan Hovanec, Beate Pesch, et al.
Urologic Oncology|September 20, 2016
Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelinesBernd J Schmitz-Dräger, Eva C Kuckuck, Tahlita C M Zuiverloon, et al.
European Urology Oncology|April 25, 2019
Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder CancerStephen B Williams, Hogan K Hudgins, Mohamed D Ray-Zack, et al.
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological reviewMarit Ahrens, John Haanen, Laurence Albiges, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
European Urology|May 9, 2015
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell CancerChristian Eichelberg, Walter L Vervenne, Maria De Santis, et al.
Future Oncology (London, England)|November 24, 2025
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tractThomas Powles, Scott T Tagawa, Christof Vulsteke, et al.
Urologic Oncology|March 23, 2020
Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trialNatalya Benderska-Söder, Jan Hovanec, Beate Pesch, et al.
Urologic Oncology|September 20, 2016
Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelinesBernd J Schmitz-Dräger, Eva C Kuckuck, Tahlita C M Zuiverloon, et al.
European Urology Oncology|April 25, 2019
Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder CancerStephen B Williams, Hogan K Hudgins, Mohamed D Ray-Zack, et al.
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological reviewMarit Ahrens, John Haanen, Laurence Albiges, et al.
Pageof 11